List of Excipients in Branded Drug TIVICAY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
RPK Pharmaceuticals Inc	TIVICAY	dolutegravir sodium	53002-1810	CELLULOSE, MICROCRYSTALLINE	2030-06-08
RPK Pharmaceuticals Inc	TIVICAY	dolutegravir sodium	53002-1810	FERRIC OXIDE YELLOW	2030-06-08
RPK Pharmaceuticals Inc	TIVICAY	dolutegravir sodium	53002-1810	MANNITOL	2030-06-08
RPK Pharmaceuticals Inc	TIVICAY	dolutegravir sodium	53002-1810	POLYETHYLENE GLYCOL	2030-06-08
RPK Pharmaceuticals Inc	TIVICAY	dolutegravir sodium	53002-1810	POLYVINYL ALCOHOL	2030-06-08
RPK Pharmaceuticals Inc	TIVICAY	dolutegravir sodium	53002-1810	POVIDONE	2030-06-08
RPK Pharmaceuticals Inc	TIVICAY	dolutegravir sodium	53002-1810	SODIUM STARCH GLYCOLATE TYPE A CORN	2030-06-08

TIVICAY Excipient Strategy, Formulation Patents, Generic Entry and Commercial Opportunities

Last updated: August 24, 2026

TIVICAY is dolutegravir sodium, an integrase strand transfer inhibitor marketed by ViiV Healthcare. Its excipient platform is relatively conventional: mannitol, microcrystalline cellulose, povidone, sodium starch glycolate and sodium stearyl fumarate in the core, with film-coating excipients for conventional tablets. The commercial opportunity is therefore less likely to come from substituting routine tablet excipients and more likely to arise from pediatric delivery, taste masking, fixed-dose combinations, low-cost manufacturing, geographic supply, and differentiated oral delivery systems.

The main technical constraint is dolutegravir’s interaction with polyvalent cations. Calcium, magnesium, aluminum and iron can reduce dolutegravir exposure when administered improperly. Excipient selection, administration instructions and product labeling must control that risk. [1]

What excipients are used in TIVICAY tablets?

The U.S. TIVICAY tablets contain the following inactive ingredients:

Formulation element	Excipient or material	Primary function
Tablet core	D-mannitol	Diluent, mouthfeel modifier
Tablet core	Microcrystalline cellulose	Filler and compression aid
Tablet core	Povidone K29/32	Binder
Tablet core	Sodium starch glycolate	Disintegrant
Tablet core	Sodium stearyl fumarate	Lubricant
Film coating	Hypromellose	Film former
Film coating	Macrogol, also known as polyethylene glycol	Plasticizer
Film coating	Titanium dioxide and iron oxide pigments, depending on strength	Opacity and color

The TIVICAY label identifies 10 mg, 25 mg and 50 mg film-coated tablets. The label also identifies TIVICAY PD, a 5 mg dispersible tablet intended for pediatric use. Its core uses the same general excipient architecture, with differences in presentation and administration requirements. [1]

The formulation is designed for immediate release rather than prolonged release. The excipient system supports robust compression, rapid disintegration and high-volume manufacture. It does not indicate a technically complex lipid, amorphous solid dispersion or modified-release platform.

How does dolutegravir’s chemistry affect excipient selection?

Dolutegravir has a metal-chelating pharmacology that directly affects formulation and administration. Polyvalent cations can bind dolutegravir in the gastrointestinal tract and reduce systemic exposure. The issue applies to antacids and mineral supplements, and it can also affect products containing calcium or iron under certain dosing conditions. [1]

Key formulation constraints

A commercial dolutegravir formulation should address:

1. Chemical and physical compatibility with mineral-containing excipients.
2. Rapid disintegration and dissolution at the intended dose.
3. Consistent content uniformity at low pediatric strengths.
4. Acceptable taste for dispersible or chewable administration.
5. Limited hygroscopicity and adequate tablet stability.
6. Compatibility with high-speed compression and coating equipment.

Routine excipients such as mannitol, microcrystalline cellulose and povidone do not inherently create the same interaction concern as calcium, magnesium or aluminum salts. Formulators should still evaluate trace elemental impurities, excipient variability and processing-related changes in dissolution.

Mannitol is commercially attractive because it provides a relatively clean mouthfeel and is widely used in orally disintegrating and pediatric products. Microcrystalline cellulose supports tablet strength but can produce a chalky texture or suspension characteristics that require optimization in dispersible formulations. Povidone improves granule and tablet cohesion. Sodium starch glycolate supports rapid break-up of the tablet matrix.

What formulation opportunities exist for TIVICAY and generic dolutegravir?

The highest-value opportunities are in dosage-form differentiation rather than simple substitution of one standard excipient for another.

Pediatric dispersible tablets

TIVICAY PD is the clearest formulation opportunity. Pediatric HIV treatment requires dose flexibility, administration with water or directly into the mouth, acceptable taste, and accurate dosing across body-weight bands. [1]

Potential commercial improvements include:

• Better taste masking without delaying dissolution.
• Smaller tablet size at equivalent dose.
• Lower friability during bottle handling.
• Improved dispersibility in limited water volumes.
• Packaging that reduces moisture uptake.
• Scored or unit-dose presentations for weight-based dosing.
• Improved acceptability for infants and young children.

Taste-masking systems must be selected carefully. Hydrophobic coatings, ion-exchange resins and lipid-based barriers can slow dolutegravir release. A generic manufacturer would need to demonstrate that any taste-masking approach does not materially alter dissolution, bioavailability or administration instructions.

Orally disintegrating tablets

An orally disintegrating dolutegravir tablet could support patients with swallowing difficulty and reduce dependence on water. The product would require rapid disintegration, adequate mechanical strength and palatability.

Commercial differentiation could come from:

• Co-processed mannitol systems.
• Low-force compression formulations.
• Sublimation or porous-tablet technologies.
• Direct-compression systems with improved mouthfeel.
• Unit-dose blister packaging.

The principal regulatory challenge is showing that the new dosage form remains therapeutically interchangeable or clinically appropriate under the applicable FDA pathway.

Granules, mini-tablets and sprinkle products

Granules and mini-tablets may improve pediatric dosing flexibility. They can be administered with soft food or liquids, subject to product-specific labeling and stability data. These formats could compete with dispersible tablets where caregivers need flexible dose adjustment.

Mini-tablets create a content-uniformity challenge, especially at low strengths. Granule coating must control taste without producing delayed release or dose segregation.

Long-acting and implantable delivery

Long-acting dolutegravir is a more substantial development opportunity but is not an ordinary excipient substitution. It would require a new delivery platform, such as a nanosuspension, depot injection or implant. The active ingredient’s low aqueous solubility and pharmacokinetics could support controlled-release development, but the clinical, manufacturing and regulatory burden would be materially higher than for an oral generic.

What is the Orange Book status of TIVICAY?

TIVICAY is an FDA-approved small-molecule drug and its relevant U.S. patents are listed in the FDA Orange Book. Orange Book data must be reviewed by product strength and dosage form because patent listings and regulatory exclusivity can differ between conventional tablets and pediatric dispersible tablets. [2]

The principal listed patent family historically associated with dolutegravir includes U.S. Patent No. 8,129,430, covering carbamoyl pyridone compounds and related integrase inhibitors. Other patents may cover salts, crystalline forms, formulations, combinations or methods of use. Patent term and listing status should be taken from the current Orange Book record rather than inferred from the original approval date.

Regulatory element	TIVICAY position
Active ingredient	Dolutegravir sodium
FDA product type	Small-molecule prescription drug
Initial U.S. approval	2013
Reference products	TIVICAY tablets and TIVICAY PD dispersible tablets
Core patent issue	Dolutegravir compound and related patent families
Formulation issue	Dispersible pediatric presentation and product-specific claims
Biosimilar pathway	Not applicable
Generic pathway	ANDA under section 505(j), subject to patent and exclusivity status

A formulation containing the same active ingredient and a different excipient system generally does not avoid an active-ingredient patent. It may avoid a narrow formulation patent if the claims require particular excipients, ratios, manufacturing steps or release characteristics.

When does TIVICAY lose exclusivity?

TIVICAY’s market exclusivity depends on several separate dates:

• Patent expiration.
• FDA-granted regulatory exclusivity.
• Pediatric exclusivity.
• The scope of Orange Book-listed patents.
• Any ANDA settlement or authorized-generic arrangement.
• Patent litigation outcomes.

The initial U.S. approval in 2013 does not establish the generic-entry date. Compound patents, patent-term adjustment, patent-term extension and pediatric exclusivity can materially change the timing.

The most important commercial date is the earliest legally permitted ANDA launch date after accounting for listed patents and regulatory exclusivity. A generic manufacturer may file an ANDA before patent expiry and certify against listed patents, but commercial launch can trigger patent litigation and a 30-month stay under the Hatch-Waxman framework. [3]

Have generic companies filed Paragraph IV challenges to TIVICAY?

A Paragraph IV challenge requires an ANDA applicant to assert that a listed patent is invalid, unenforceable or not infringed. The applicant must provide a certification notice to the patent owner and reference-product sponsor.

For TIVICAY, the relevant diligence points are:

Question	Commercial significance
Which patent is challenged?	Determines whether a compound, salt, formulation or method claim is at issue
Is a notice letter public?	Can identify the challenger and litigation trigger
Was a suit filed within 45 days?	Determines whether a 30-month stay may apply
Is a settlement disclosed?	May establish an agreed launch date
Does the ANDA cover all strengths?	Affects volume and substitution potential
Does the filing cover TIVICAY PD?	Determines pediatric competitive exposure

An excipient redesign does not eliminate the need to address compound-patent claims. A design-around is most useful when the remaining patent estate is concentrated in a specific formulation or manufacturing claim.

No biosimilar pathway applies because dolutegravir is a chemically synthesized small molecule, not a biologic regulated under the Public Health Service Act.

What manufacturing and excipient IP barriers affect generic dolutegravir?

Manufacturing barriers are more likely to arise from process control and product performance than from access to common excipients.

Key technical barriers include:

• Producing consistent dolutegravir sodium particle size.
• Controlling polymorphic or crystalline form.
• Achieving low-dose content uniformity in pediatric tablets.
• Maintaining dissolution across commercial-scale batches.
• Preventing segregation between active ingredient and low-density excipients.
• Controlling residual solvents and elemental impurities.
• Maintaining stability under heat and humidity.
• Reproducing color and coating performance.
• Demonstrating bioequivalence for modified or pediatric presentations.

Common excipients are generally available from multiple suppliers. Supply-chain value is highest where a manufacturer can offer:

• Direct-compression grades with tighter particle-size distribution.
• Low-nitrite or low-peroxide excipients.
• Moisture-controlled mannitol.
• Co-processed filler-binder systems.
• Taste-masking polymers with rapid release.
• High-purity lubricants with low variability.
• Regional supply and validated alternate sources.

An excipient supplier generally cannot claim ownership of the TIVICAY formulation merely by selling an excipient used in it. Value increases when the supplier owns a composition, co-processing, particle-engineering or manufacturing patent that materially improves the finished dosage form.

How does TIVICAY compare with competing dolutegravir products?

TIVICAY competes within a broader dolutegravir franchise rather than as an isolated tablet. ViiV markets dolutegravir in combination products including Triumeq, Dovato and Juluca. These products use different active-ingredient combinations and may carry separate formulation, combination and method-of-use patent issues. [4]

Product	Active-ingredient structure	Excipient opportunity	Competitive issue
TIVICAY	Dolutegravir alone	Pediatric, ODT, dispersible and low-cost tablet formats	Direct generic substitution
TIVICAY PD	Pediatric dolutegravir	Taste masking, mini-tablets, flexible dosing	Pediatric adherence and procurement
Dovato	Dolutegravir plus lamivudine	Bilayer, co-compression and compatibility optimization	Fixed-dose combination patents
Triumeq	Dolutegravir, abacavir and lamivudine	Multi-API segregation and stability control	Combination-product patent estate
Juluca	Dolutegravir plus rilpivirine	Release and food-effect management	Combination and method-of-use claims

The commercial attractiveness of TIVICAY generic entry depends on whether prescribers and payers favor the single-agent product or fixed-dose combinations. In many treatment settings, combination products reduce pill burden and may command stronger formulary positioning.

What licensing deals and commercial partnerships affect TIVICAY?

ViiV’s dolutegravir commercial model includes licensing and access arrangements, particularly in lower-income countries and public-health procurement channels. Voluntary licensing and procurement agreements can permit qualified manufacturers to supply generic dolutegravir in defined territories while limiting commercial rights in higher-income markets. [5]

For excipient companies, these arrangements create demand for:

• Low-cost, globally scalable tablet platforms.
• Pediatric dosage forms.
• Stable formulations for hot and humid climates.
• Local or regional manufacturing support.
• Alternate-source qualification.
• Public-sector packaging and distribution formats.

Geographic freedom to operate must be assessed separately. A formulation that avoids a U.S. formulation patent may remain blocked by compound or formulation rights in Europe, Japan, China, India or other jurisdictions. Patent term, national-phase prosecution and voluntary-license territory restrictions can produce different launch dates by country.

What generic launch scenarios exist for TIVICAY?

Three commercial launch scenarios are most relevant.

Early negotiated entry

An ANDA applicant reaches a settlement with the sponsor and receives a defined launch date before full patent expiry. The value depends on the settlement terms, authorized-generic restrictions and whether the agreement covers TIVICAY PD.

At-risk launch

A generic company launches before final resolution of patent litigation. This can accelerate revenue but exposes the company to damages, injunction risk and inventory impairment if the patent holder prevails.

Post-expiry entry

Multiple generic manufacturers launch after patent and exclusivity barriers expire. Prices typically decline rapidly, making manufacturing cost, supply reliability and payer access more important than minor excipient differentiation.

The strongest commercial position is usually a differentiated pediatric or administration-friendly product launched before the market becomes fully commoditized, provided the product has a legally defensible formulation and a clear regulatory pathway.

How strong is the TIVICAY patent estate?

The estate is strongest where compound claims, salt or crystalline-form claims and combination claims overlap. A simple excipient substitution is unlikely to create a meaningful design-around against a valid compound patent.

Patent strength is more limited for conventional tablet excipients unless the claims require a narrow composition or manufacturing process. The most defensible formulation opportunities are likely to involve:

• A specific pediatric dispersible composition.
• A taste-masked formulation with defined release characteristics.
• A stable low-dose dosage form.
• A novel solid-state form.
• A manufacturing process that produces a defined particle or polymorph profile.
• A fixed-dose combination with specific excipient architecture.

Freedom-to-operate analysis should map each claim against the proposed active form, dosage form, excipient identity, excipient concentration, process steps and geographic market.

What is the revenue exposure to TIVICAY generic entry?

Revenue exposure is not limited to TIVICAY tablet sales. Generic entry can affect the broader dolutegravir franchise if lower-priced single-agent products influence treatment selection, procurement policy or combination-product pricing.

The principal exposure variables are:

• TIVICAY net sales by territory.
• Volume in government and institutional channels.
• Share of pediatric prescriptions.
• Switching between single-agent and fixed-dose combination products.
• Number of ANDA entrants.
• Authorized-generic arrangements.
• Reimbursement substitution rules.
• Patent settlement timing.
• Manufacturing cost per tablet.

The first generic entrant can capture disproportionate value if it has 180-day exclusivity after a first-to-file Paragraph IV challenge. Later entrants face steeper price erosion and must compete on supply continuity, quality records, packaging and procurement access.

Key Takeaways

• TIVICAY uses a conventional immediate-release tablet excipient system centered on mannitol, microcrystalline cellulose, povidone, sodium starch glycolate and sodium stearyl fumarate.
• Dolutegravir’s interaction with polyvalent cations is the principal excipient and administration constraint.
• The strongest formulation opportunities are pediatric dispersible tablets, orally disintegrating tablets, mini-tablets, granules and taste-masked products.
• Common excipients are unlikely to provide meaningful patent protection by themselves.
• A redesigned excipient system does not avoid dolutegravir compound patents.
• TIVICAY is subject to Orange Book, Hatch-Waxman and ANDA considerations, not biosimilar regulation.
• Generic entry timing depends on current patent listings, regulatory exclusivity, Paragraph IV litigation and settlement terms.
• Excipient suppliers can capture value through co-processed systems, low-variability materials, taste masking, moisture control and regional supply.
• The commercial opportunity is stronger in pediatric and public-health formulations than in an undifferentiated adult tablet.
• Combination products such as Dovato, Triumeq and Juluca must be analyzed separately because their patent and commercial exposure differs from TIVICAY.

FAQs

Can a generic manufacturer use different excipients from TIVICAY?

Yes. An ANDA applicant may use a different inactive-ingredient system if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability and labeling.

Are TIVICAY’s excipients themselves patented?

Common excipients such as mannitol, microcrystalline cellulose and povidone are not proprietary to TIVICAY. Specific combinations, ratios, processing methods or pediatric delivery systems may be separately protected.

Does calcium in a tablet automatically make a dolutegravir formulation infringing or unsafe?

No. The issue is whether the calcium or other polyvalent cation affects dolutegravir availability or creates a labeling and administration problem. Product-specific compatibility, dissolution and clinical evaluation are required.

Is TIVICAY PD a separate generic opportunity from adult TIVICAY?

Yes. The pediatric dispersible product may require separate formulation development, regulatory strategy, labeling analysis and patent review, even though both products contain dolutegravir.

Which excipient technologies have the highest commercial value for dolutegravir?

Taste masking, moisture-stable pediatric systems, low-dose content-uniformity platforms, rapidly dispersible tablets and co-processed direct-compression excipients have the clearest potential.

References

1. U.S. Food and Drug Administration. (2024). TIVICAY (dolutegravir sodium) tablets and TIVICAY PD prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards.
4. ViiV Healthcare. (2024). HIV medicines and product information.
5. Medicines Patent Pool. (2024). Dolutegravir licensing and access agreements.